Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ryan M. Bagaric"'
Autor:
Cara A. Timpani, Stephanie Kourakis, Danielle A. Debruin, Dean G. Campelj, Nancy Pompeani, Narges Dargahi, Angelo P. Bautista, Ryan M. Bagaric, Elya J. Ritenis, Lauren Sahakian, Didier Debrincat, Nicole Stupka, Patricia Hafner, Peter G. Arthur, Jessica R. Terrill, Vasso Apostolopoulos, Judy B. de Haan, Nuri Guven, Dirk Fischer, Emma Rybalka
Publikováno v:
JCI Insight, Vol 8, Iss 21 (2023)
New medicines are urgently required to treat the fatal neuromuscular disease Duchenne muscular dystrophy (DMD). Dimethyl fumarate (DMF) is a potent immunomodulatory small molecule nuclear erythroid 2-related factor 2 activator with current clinical u
Externí odkaz:
https://doaj.org/article/2f67a5d7f78e4aa7850dc5cf476bf2a1
Autor:
Emma Rybalka, Cara A. Timpani, Danielle A. Debruin, Ryan M. Bagaric, Dean G. Campelj, Alan Hayes
Publikováno v:
Cells, Vol 9, Iss 12, p 2657 (2020)
Myostatin inhibition therapy has held much promise for the treatment of muscle wasting disorders. This is particularly true for the fatal myopathy, Duchenne Muscular Dystrophy (DMD). Following on from promising pre-clinical data in dystrophin-deficie
Externí odkaz:
https://doaj.org/article/2c6703cccd9d49de9fcd3f0d6c2790da
Autor:
Cara A. Timpani, Stephanie Kourakis, Danielle A. Debruin, Dean G. Campelj, Nancy Pompeani, Narges Dargahi, Angelo P. Bautista, Ryan M. Bagaric, Elya J. Ritenis, Lauren Sahakian, Patricia Hafner, Peter G. Arthur, Jessica R. Terrill, Vasso Apostolopoulos, Judy B. de Haan, Nuri Guven, Dirk Fischer, Emma Rybalka
New medicines are urgently required to treat the fatal neuromuscular disease, Duchenne muscular dystrophy (DMD). DMD involves progressive muscle damage and weakness, which are preceded by oxidative stress, inflammation, and mitochondrial dysfunction.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17d6520d99980bdf3aa1539b4cbf92e6
https://doi.org/10.1101/2022.09.15.508124
https://doi.org/10.1101/2022.09.15.508124
Publikováno v:
Cells, Vol 9, Iss 2657, p 2657 (2020)
Cells
Cells
Myostatin inhibition therapy has held much promise for the treatment of muscle wasting disorders. This is particularly true for the fatal myopathy, Duchenne Muscular Dystrophy (DMD). Following on from promising pre-clinical data in dystrophin-deficie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::787d2e675a2e3e644782b01152b05951
https://doi.org/10.3390/cells9122657
https://doi.org/10.3390/cells9122657